{"title":"Antiphospholipid antibody syndrome","authors":"Jyoti R. Parida , Durga Prasanna Misra , Anupam Wakhlu , Vikas Agarwal","doi":"10.1016/j.cqn.2014.03.007","DOIUrl":null,"url":null,"abstract":"<div><p>Antiphospholipid antibody syndrome (APS) is characterized by recurrent pregnancy losses and/or thrombotic events (both arterial and venous) with persistently positive lupus anticoagulant or antiphospholipid antibodies. Activation of complements, platelets and endothelial cells by the anticardiolipin-β2GP-1 complex plays a major role in pathogenesis of thrombosis. Treatment is with anticoagulation (warfarin/heparin), with steroids needed in the presence of catastrophic APS or cytopenias. Upto a third of patients may have significant long term morbidity.</p></div>","PeriodicalId":100275,"journal":{"name":"Clinical Queries: Nephrology","volume":"3 1","pages":"Pages 9-14"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cqn.2014.03.007","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Queries: Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211947714000089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Antiphospholipid antibody syndrome (APS) is characterized by recurrent pregnancy losses and/or thrombotic events (both arterial and venous) with persistently positive lupus anticoagulant or antiphospholipid antibodies. Activation of complements, platelets and endothelial cells by the anticardiolipin-β2GP-1 complex plays a major role in pathogenesis of thrombosis. Treatment is with anticoagulation (warfarin/heparin), with steroids needed in the presence of catastrophic APS or cytopenias. Upto a third of patients may have significant long term morbidity.